Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 EUR | -2.54% | -6.50% | -88.32% |
06-24 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index | CI |
06-17 | Sector Update: Health Care Stocks Decline Premarket Monday | MT |
Sales 2024 * | 39.35M 36.74M 3.11B | Sales 2025 * | 58.17M 54.31M 4.6B | Capitalization | 64.27M 60M 5.08B |
---|---|---|---|---|---|
Net income 2024 * | -119M -111M -9.41B | Net income 2025 * | -78M -72.82M -6.17B | EV / Sales 2024 * | -1.61 x |
Net cash position 2024 * | 127M 119M 10.08B | Net cash position 2025 * | 54.53M 50.91M 4.31B | EV / Sales 2025 * | 0.17 x |
P/E ratio 2024 * |
-0.59
x | P/E ratio 2025 * |
-1.13
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 week | -6.50% | ||
Current month | -12.21% | ||
1 month | -16.06% | ||
3 months | -85.89% | ||
6 months | -88.14% | ||
Current year | -88.32% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 04/09/18 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 11/04/21 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 05/11/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 30/11/08 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 04/09/18 |
Elan Ezickson
BRD | Director/Board Member | 60 | 11/12/19 |
Date | Price | Change |
---|---|---|
28/06/24 | 1.15 | -2.54% |
27/06/24 | 1.18 | -4.07% |
26/06/24 | 1.23 | -2.38% |
25/06/24 | 1.26 | +5.00% |
24/06/24 | 1.2 | -2.44% |
Delayed Quote Börse Stuttgart, June 28, 2024 at 03:14 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- MRNS Stock
- 61Y Stock